Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma
Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma
复制标题
DOI：
10.1111/his.13775
复制
发表时间：
2019-03-01
期刊：
影响因子：
6.4
通讯作者：
Takeshima, Yukio
中科院分区：
文献类型：
--
作者：
Kai, Yuichiro;Amatya, Vishwa J.;Takeshima, Yukio
目的 上皮样间皮瘤和肺腺癌的鉴别诊断进程不断取得进展；然而，没有绝对的免疫组织化学标记物可以明确诊断上皮样间皮瘤。本研究的目的是寻找上皮样间皮瘤的新型阴性标记物。方法和结果 我们通过免疫组织化学研究了粘蛋白 21 (MUC21) 作为上皮样间皮瘤的新型阴性诊断标记物的适用性，该粘蛋白 21 在我们之前的研究中被鉴定。通过使用免疫组织化学研究了 70 例上皮样间皮瘤和 70 例肺腺癌的 MUC21 以及其他先前报道的标记物的表达。 MUC21 仅在 70 例上皮样间皮瘤中表达，而 70 例肺腺癌中有 67 例 (96%) 表达。 MUC21阴性表达区分上皮样间皮瘤和肺腺癌的敏感性、特异性和准确性分别为97%、96%和96%；这些与癌胚抗原和claudin-4相似，并且优于甲状腺转录因子1、napsin-A和粘蛋白4。 结论 MUC21可以作为一种额外的、新型的、阴性的免疫组化标记物来区分间皮瘤和肺腺癌。
Aims The process of differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma has been progressing; however, there are no absolute immunohistochemical markers with which to definitively diagnose epithelioid mesothelioma. The aim of this study was to search for a novel negative marker of epithelioid mesothelioma. Methods and results We immunohistochemically studied the applicability of mucin 21 (MUC21), which was identified in our previous study, as a novel, negative diagnostic marker for epithelioid mesothelioma. Seventy epithelioid mesotheliomas and 70 lung adenocarcinomas were investigated for the expression of MUC21, along with other previously reported markers, by the use of immunohistochemistry. MUC21 was expressed in only two of the 70 (3%) epithelioid mesotheliomas, as compared with 67 of the 70 (96%) lung adenocarcinomas. The sensitivity, specificity and accuracy of negative MUC21 expression for differentiating epithelioid mesothelioma from lung adenocarcinoma were 97%, 96%, and 96%, respectively; these are similar to those of carcinoembryonic antigen and claudin-4, and better than those of thyroid transcription factor-1, napsin-A, and mucin 4. Conclusion MUC21 could be used as an additional, novel, negative immunohistochemical marker to differentiate mesothelioma from lung adenocarcinoma.